Role of angiopoietin‑2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion‑induced injury in H9c2 cardiomyocytes

Hu,Shuoqiang; Cao,Shujun; Liu,Jinghua

doi:10.3892/etm.2017.4564

Role of angiopoietin‑2 in the cardioprotective effect of fibroblast growth factor 21 on ischemia/reperfusion‑induced injury in H9c2 cardiomyocytes

Authors:
- Shuoqiang Hu
- Shujun Cao
- Jinghua Liu
View Affiliations

Affiliations: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing 100029, P.R. China, Department of Cardiology, Beijing Daxing Hospital, Capital Medical University, Beijing 102600, P.R. China
Published online on: June 8, 2017 https://doi.org/10.3892/etm.2017.4564
Pages: 771-779
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor 21 (FGF21) exerts a protective effect in ischemia/reperfusion (I/R)‑induced cardiac injury. However, the exact molecular mechanism underlying the FGF21 action remains unclear. The present study aimed to evaluate the role of angiopoietin‑2 (Angpt2) in the cardioprotective effect of FGF21. For this purpose, the H9C2 cell line was subjected to simulated I/R or aerobic conditions with or without FGF21 administration. Certain groups were also transfected with Angpt2 small interfering RNA (siRNA). Cell viability, apoptosis rate and cell migration were examined, and the expression levels of Angpt2, glucose transporter 1 (GLUT1) and caspase‑3 were measured by quantitative polymerase chain reaction (qPCR) and western blot analyses. The results demonstrated that FGF21 administration suppressed apoptosis and increased the cell migration ability following I/R‑induced injury. qPCR and western blot data showed a decreased level of GLUT1 after I/R‑induced injury, which was reversed by FGF21 administration. Furthermore, inhibition of Angpt2 expression using siRNA enhanced the cardioprotective effect of FGF21 by upregulation of GLUT1. In conclusion, FGF21 administration protected against I/R‑induced injury in cardiomyocytes, and further inhibition of Angpt2 with FGF21 administration induced the expression of GLUT1, which may promote the energy metabolism in cardiomyocytes, consequently resulting in a more efficient cardioprotective effect. These results suggested that FGF21 administration and inhibition of Angpt2 could be a novel therapeutic approach for I/R‑induced cardiac injury.

View Figures

View References

1	Ambrose JA and Singh M: Pathophysiology of coronary artery disease leading to acute coronary syndromes. F1000Prime Rep. 7:082015. View Article : Google Scholar : PubMed/NCBI
2	Hausenloy DJ and Yellon DM: Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest. 123:92–100. 2013. View Article : Google Scholar : PubMed/NCBI
3	de Groot H and Rauen U: Ischemia-reperfusion injury: Processes in pathogenetic networks: A review. Transplant Proc. 39:pp. 481–484. 2007; View Article : Google Scholar : PubMed/NCBI
4	Boag SE, Das R, Shmeleva EV, Bagnall A, Egred M, Howard N, Bennaceur K, Zaman A, Keavney B and Spyridopoulos I: T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients. J Clin Invest. 125:3063–3076. 2015. View Article : Google Scholar : PubMed/NCBI
5	Zitta K, Meybohm P, Bein B, Gruenewald M, Lauer F, Steinfath M, Cremer J, Zacharowski K and Albrecht M: Activities of cardiac tissue matrix metalloproteinases 2 and 9 are reduced by remote ischemic preconditioning in cardiosurgical patients with cardiopulmonary bypass. J Transl Med. 12:942014. View Article : Google Scholar : PubMed/NCBI
6	He K, Yan L, Pan CS, Liu YY, Cui YC, Hu BH, Chang X, Li Q, Sun K, Mao XW, et al: ROCK-dependent ATP5D modulation contributes to the protection of notoginsenoside NR1 against ischemia-reperfusion-induced myocardial injury. Am J Physiol Heart Circ Physiol. 307:H1764–H1776. 2014. View Article : Google Scholar : PubMed/NCBI
7	Sawicki G: Synergistic effect of inhibitors of MMPs and ROS-dependent modifications of contractile proteins on protection hearts subjected to oxidative stress. Curr Pharm Des. 20:1345–1348. 2014. View Article : Google Scholar : PubMed/NCBI
8	Fukumoto S: Actions and mode of actions of FGF19 subfamily members. Endocr J. 55:23–31. 2008. View Article : Google Scholar : PubMed/NCBI
9	Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H and Gromada J: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 55:2470–2478. 2006. View Article : Google Scholar : PubMed/NCBI
10	Liu SQ, Roberts D, Kharitonenkov A, Zhang B, Hanson SM, Li YC, Zhang LQ and Wu YH: Endocrine protection of ischemic myocardium by FGF21 from the liver and adipose tissue. Sci Rep. 3:27672013. View Article : Google Scholar : PubMed/NCBI
11	Ge X, Chen C, Hui X, Wang Y, Lam KS and Xu A: Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem. 286:34533–34541. 2011. View Article : Google Scholar : PubMed/NCBI
12	Syrjälä SO, Tuuminen R, Nykänen AI, Raissadati A, Dashkevich A, Keränen MA, Arnaudova R, Krebs R, Leow CC, Saharinen P, et al: Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts. Am J Transplant. 14:1096–1108. 2014. View Article : Google Scholar : PubMed/NCBI
13	Lukasz A, Beutel G, Kümpers P, Denecke A, Westhoff-Bleck M, Schieffer B, Bauersachs J, Kielstein JT and Tutarel O: Angiopoietin-2 in adults with congenital heart disease and heart failure. PLoS One. 8:e668612013. View Article : Google Scholar : PubMed/NCBI
14	Pöss J, Ukena C, Kindermann I, Ehrlich P, Fuernau G, Ewen S, Mahfoud F, Kriechbaum S, Böhm M and Link A: Angiopoietin-2 and outcome in patients with acute decompensated heart failure. Clin Res Cardiol. 104:380–387. 2015. View Article : Google Scholar : PubMed/NCBI
15	Scholz A, Plate KH and Reiss Y: Angiopoietin-2: A multifaceted cytokine that functions in both angiogenesis and inflammation. Ann NY Acad Sci. 1347:45–51. 2015. View Article : Google Scholar : PubMed/NCBI
16	Winter SF, Acevedo VD, Gangula RD, Freeman KW, Spencer DM and Greenberg NM: Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. Oncogene. 26:4897–4907. 2007. View Article : Google Scholar : PubMed/NCBI
17	Lu Z, Chen Y, Li L, Wang G, Xue H and Tang W: Combination therapy of renin-angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: A systematic review and meta-analysis. J Hum Hypertens. 31:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med. 357:1121–1135. 2007. View Article : Google Scholar : PubMed/NCBI
20	Liu SQ, Tefft BJ, Roberts DT, Zhang LQ, Ren Y, Li YC, Huang Y, Zhang D, Phillips HR and Wu YH: Cardioprotective proteins upregulated in the liver in response to experimental myocardial ischemia. Am J Physiol Heart Circ Physiol. 303:H1446–H1458. 2012. View Article : Google Scholar : PubMed/NCBI
21	Liu SQ and Wu YH: Liver cell-mediated alleviation of acute ischemic myocardial injury. Front Biosci (Elite Ed). 2:711–724. 2010. View Article : Google Scholar : PubMed/NCBI
22	Planavila A, Redondo-Angulo I and Villarroya F: FGF21 and Cardiac Physiopathology. Front Endocrinol (Lausanne). 6:1332015.PubMed/NCBI
23	Patel V, Adya R, Chen J, Ramanjaneya M, Bari MF, Bhudia SK, Hillhouse EW, Tan BK and Randeva HS: Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts. PLoS One. 9:e871022014. View Article : Google Scholar : PubMed/NCBI
24	Cong WT, Ling J, Tian HS, Ling R, Wang Y, Huang BB, Zhao T, Duan YM, Jin LT and Li XK: Proteomic study on the protective mechanism of fibroblast growth factor 21 to ischemia-reperfusion injury. Can J Physiol Pharmacol. 91:973–984. 2013. View Article : Google Scholar : PubMed/NCBI
25	Zhang Y, Li H, Wei R, Ma J, Zhao Y, Lian Z and Liu Z: Endothelial cells regulate cardiac myocyte reorganisation through β1-integrin signalling. Cell Physiol Biochem. 35:1808–1820. 2015. View Article : Google Scholar : PubMed/NCBI
26	Qian H, Yang Y, Li J, Huang J, Dou K and Yang G: The role of vascular stem cells in atherogenesis and post-angioplasty restenosis. Ageing Res Rev. 6:109–127. 2007. View Article : Google Scholar : PubMed/NCBI
27	Tanajak P, Chattipakorn SC and Chattipakorn N: Effects of fibroblast growth factor 21 on the heart. J Endocrinol. 227:R13–R30. 2015. View Article : Google Scholar : PubMed/NCBI
28	Ji K, Zheng J, Lv J, Xu J, Ji X, Luo YB, Li W, Zhao Y and Yan C: Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR-YY1-PGC1α pathway. Free Radic Biol Med. 84:161–170. 2015. View Article : Google Scholar : PubMed/NCBI
29	Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, Otto KA, Reifel-Miller A and Kharitonenkov A: Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol. 210:1–6. 2007. View Article : Google Scholar : PubMed/NCBI
30	Fiedler U, Krissl T, Koidl S, Weiss C, Koblizek T, Deutsch U, Martiny-Baron G, Marmé D and Augustin HG: Angiopoietin-1 and angiopoietin-2 share the same binding domains in the Tie-2 receptor involving the first Ig-like loop and the epidermal growth factor-like repeats. J Biol Chem. 278:1721–1727. 2003. View Article : Google Scholar : PubMed/NCBI
31	Lorbeer R, Baumeister SE, Dörr M, Nauck M, Grotevendt A, Volzke H, Vasan RS, Wallaschofski H and Lieb W: Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur J Heart Fail. 15:1327–1334. 2013. View Article : Google Scholar : PubMed/NCBI
32	Wang X, Yong H, Mi L, Bai Y, Guo L, Gao W, Cui M and Zhang Y: Changes and significance of serum angiopoietin-2 levels in patients with coronary heart disease. Biomarkers. 17:745–749. 2012. View Article : Google Scholar : PubMed/NCBI
33	Piccolo MT, Menale C and Crispi S: Combined anticancer therapies: An overview of the latest applications. Anticancer Agents Med Chem. 15:408–422. 2015. View Article : Google Scholar : PubMed/NCBI
34	Smith R, McCready T and Yusuf S: Combination therapy to prevent cardiovascular disease: Slow progress. JAMA. 309:1595–1596. 2013. View Article : Google Scholar : PubMed/NCBI
35	Cadete VJ, Arcand SA, Lin HB and Sawicki G: Synergistic protection of MLC 1 against cardiac ischemia/reperfusion-induced degradation: A novel therapeutic concept for the future. Future Med Chem. 5:389–398. 2013. View Article : Google Scholar : PubMed/NCBI